In our November issue of Pharmaceutical Executive
FEATURES
Cover Story
Pharm Exec's 2019 Pipeline Report
Joseph Constance
This year's Pipeline Report sees CAR-T therapy eyeing new territory, cannabis-based agents targeting CNS and rare genetic disorders, the advancement of non-opioid alternatives, and the untangling of the path to market for biosimilars.
Download the digital issue |
ADVERTISEMENT
Patient Assistance Centers of Excellence: The Next Generation of Brand Support
Wednesday, November 14th at 11:00 AM EST
 Register Now |
From the Editor
Steadying the Path of Good Science
Lisa Henderson
As this year's Pipeline Report illustrates, there remains an imbalance between funding and incentivizing new drug discovery in some therapeutic areas and rewarding the risk-based nature of these innovations. Imagine if we could solve this conundrum in science?
Download the digital issue |
ADVERTISEMENT
Bringing Intelligence to Drug Discovery–The Importance of Contextual Information at All Levels
On Demand
 Learn More |
Market Performance
Biopharma Business Check
Peter Young
The increase in new drug approvals and candidates in development are good signs for pharma and biotech, but both sectors face continued pricing, cost, and healthcare policy-related challenges.
Download the digital issue |
ADVERTISEMENT
Seizing Opportunities in Japan, the Second Largest Innovation-Driven Pharmaceutical Market
On Demand
 Learn More |
Emerging Biopharma
Southeast Biotech: Rising Tall in the Valley
Michelle Maskaly
Examining the booming life sciences scene in southeast Virginia and Raleigh-Durham and Winston-Salem, North Carolina–and the region's advantages in location, talent, and funding compared to the more glamour spots up north.
Download the digital issue |
ALSO IN THIS ISSUE
High-Risk Marketing Violations Draw Scrutiny
Jill Wechsler
Regulators, prosecutors shifting enforcement focus from off-label promotion to messages that raise safety issues, mislead…Read more
Fighting for a Streamlined European HTA Scheme
Reflector
Parliament throws wrench in Commission's plan to regulate HTA…Read more
Stunted Innovation in Drug Development?
Meghan Oates-Zalesky
Data shows cultural gaps and highlights a C-level fix…Read more
|
